Address of Welcome

Chairman's Introduction

The role of WHO in antileprosy drug trials

Chemotherapeutic trials and their assessments

The technique of evaluating anti-Ieprosy medications at the Forschungsinstitut Borstel

Pharmacological aspects of the chemotherapy of leprosy

Assessment of treatment procedures by means of bacteriological and histological examinations

Problems in the design of medium and long-term therapeutic trials

Chemotherapeutic trials in patients with non-lepromatous leprosy

Viability of Myco. leprae in the skin and bone marrow of patients with lepromatous leprosy while on Dapsone or Lamprene

Effect of mono treatment and combined treatment on the morphology of Myco. leprae in the skin

Treatment of leprosy with Clofazimine, Rifampicin and Bayrena

A preliminary report on a therapeutic trial with Acedapsone in Lepromatous leprosy

Low dose Dapsone therapy in lepromatous leprosy

A report on a controlled clinical trial with conventional and one third conventional dose of Dapsone administered orally once a week in lepromatous patients

Personal experience with Clofazimine in the treatment of leprosy

Long-term follow-up of Clofazimine (Lamprene) in the management of reactive phases of leprosy

The Effect of Long-term Steroid Therapy on Patients Treated with Clofazimine (Lamprene)

Open trial with Clofazimine in the management of recurrent lepra reaction and of Sulphone sensitive cases: a preliminary report

Rifampicin: the investigation of a bactericidal antileprosy drug

The use of Rifampicin in the treatment of leprosy

A controlled clinical trial of continuous and intermittent Rifampicin therapy during an initial three months period in lepromatous leprosy: final analysis

Antibiotics in leprosy, with special reference to Rifampicin

The effect of a single dose of rifampicin on the infectivity of the nasal discharge in leprosy (preliminary communication)

Results of leprosy control project, Malawi

Combined therapy in leprosy

Preliminary Experience with Combined Therapy using Rifampicin and IsoprodiaPreliminary experience with combined therapy using Rifampicin and Isoprodian (L73A)n (L73A)

Treatment of leprosy with Rifampicin and Isoprodian (L73A)

Clinical and bacteriological effects of Rifampicin in combination with L73A in leprosy: observation for six months

Treatment of leprosy with Rifampicinand Isoprodian in 38 patients at St. Thomas Hospital, Chetput, South India

Rifampicin and Isoprodian in combination in the treatment of leprosy

Preliminary experience with Rifampicin and Isoprodian (L73A) combination in lepromatous leprosy

Preliminary experience with Rifampicin and Isoprodian in combination in leprosy treatment

Report of combined therapy in leprosy with Rifampicin and Isoprodian conducted at the Bisidimo-Center, Ethiopia

Preliminary report of a drug trial conducted at leprosy relief rural centre, Chettipatty, South India

The leprosy eradication programme of Malta

Part I. Criteria for the assessment of drug activity

Part II. Current concerns in therapeutic research

Part III. Clinical trials

Part IV. Practical problems of chemotherapy in leprosy